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Glioblastoma is among the most common tumor of the central nervous system in adults.
Overall survival has not significantly improved over the last decade, even with optimizing
standard therapeutic care including extent of resection and radio- and chemotherapy.
In this article, we review features of the brain vasculature found in healthy cerebral
tissue and in glioblastoma. Brain vessels are of various sizes and composed of several
vascular cell types. Non-vascular cells such as astrocytes or microglia also interact
with the vasculature and play important roles. We also discuss in vitro engineered
artificial blood vessels which may represent useful models for better understanding
the tumor–vessel interaction. Finally, we summarize results from clinical trials with anti-
angiogenic therapy alone or in combination, and discuss the value of these approaches
for targeting glioblastoma.
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INTRODUCTION
In vertebrates, vessels are built of an internal layer made of endothelial cells which are in contact
with the blood and of mural cells that are composed of either smooth muscle cells (larger vessels)
or pericytes (in capillaries). In the brain, blood vessels are tightly organized and participate in blood
and brain tissue exchange via the blood–brain barrier (BBB).
Within the brain tumor vasculature, two different types of vessels are found, vessels formed by
angiogenesis (neoangiogenic vessels) and preexisting vessels which may be co-opted by tumor cells
(co-opted vessels). Anti-angiogenic strategies have been developed for targeting the brain tumor
vasculature (Lakka and Rao, 2008). Unfortunately, clinical trials were not crowned with success
(Chinot et al., 2014). A contributing factor is represented by a shift of tumor cells to a co-optive
mode induced by anti-angiogenic therapy which contributes to tumor spread and development
(Griveau et al., 2018).
In this article, we discuss the characteristics and specific features of the normal and brain tumor
vasculature. We will also include in our discussion in vitro constructed artificial blood vessels by
tissue engineering which represent an interesting tool to study tissue–vessel interactions and may
also be useful in the tumor context. Finally, we will review some recent clinical studies using anti-
angiogenic drugs in glioblastoma.
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THE BLOOD–BRAIN BARRIER
In a healthy individual, the central nervous system (CNS)
parenchyma is protected from the peripheral circulation by the
BBB. This barrier comprises a network of blood vessels made of
endothelial cells with unique features (Figure 1 – healthy brain).
Endothelial cells at the BBB act as gatekeepers to control soluble
factors and immune cell trafficking into the vessel wall and
underlying tissues, and both the transcellular and paracellular
pathways are involved in this process.
The Paracellular Pathway
The paracellular pathway is modulated by the coordinated
opening and closure of endothelial cell–cell junctions which
involves a complex rearrangement of endothelium-specific
transmembrane tight/adherens junction proteins and the related
cytoskeleton. CNS tight junctions are primarily formed by
Claudin5 and Occludin, and are coupled with the Zonula
Occludens intracellular proteins (ZO1, ZO2, and ZO3) which
form a scaffold between these transmembrane proteins and
the actin cytoskeleton. Other Claudins may be involved in
controlling endothelial cell paracellular barrier properties, as
Claudin5 downregulation only leads to small size molecule
leakage at the BBB (Nitta et al., 2003). Claudin1, Claudin3,
and Claudin12 have been identified as potential candidates,
but their role still needs to be clarified (Ohtsuki et al., 2008;
Daneman et al., 2010a; Kooij et al., 2014). Members of the
immunoglobulin superfamily, notably CAMs (PECAM1,
ICAM1, and VCAM1), JAMs (JAM1–3), and Nectin proteins,
clustered at CNS endothelial intercellular contacts, promote
homotypic cell–cell adhesion and regulate inflammatory cell
transmigration at the BBB (Del Maschio et al., 1999). Recent
literature suggested that tricellular contacts, where the corners
of three cells meet, can also be found in CNS endothelial
cells. Specifically, tricellulin and angulin-1/lipolysis-stimulated
lipoprotein receptor (LSR) were shown to participate to
BBB paracellular control of plasmatic protein and immune
cell trafficking (Iwamoto et al., 2014; Sohet et al., 2015).
Importantly, tight junctions cannot be dissociated from
adherent junctions in regulating BBB tightness; CNS endothelial
adherent junctions are characterized by homophilic cadherin
(VE-cadherin and N-cadherin) interactions controlling cell
adhesion. Adherent junctions are linked to the cytoskeleton
via their binding partner β-catenin and participate to
BBB tightness through phosphorylation, cleavage, and
internalization, or by modulating Claudin5 expression level
(Meng and Takeichi, 2009).
The Transcellular Pathway
Aside from the paracellular pathway, brain nutrient intake and
CNS toxin removal are highly regulated by solute transporters
and receptor-mediated transcytosis at the BBB, and inflammatory
cells are actively prevented from crossing the BBB by low levels of
immune receptors that normally permit immune trafficking.
Specifically, the cerebral endothelium expresses a number
of specific solute transporters to facilitate the carrier-mediated
transport of glucose (glucose transporters: GLUT1), amino
acids (cationic amino acid transporters: CAT1, CAT3),
monocarboxylic acids (monocarboxylate transporters: MCT1),
hormones (thyroid hormone transporters: MCT8), fatty acids
(fatty acid transporters: FATP-1), nucleotides (nucleoside
transporters: ENT1, ENT2), ions (organic anion and organic
cation transporters), amines, choline, and vitamins, which
are otherwise excluded from the brain due to the paracellular
pathway (Sweeney et al., 2019). Efflux mechanisms also
contribute to barrier functions, with ATP-binding cassette
transporters (P-gp: MDR1), breast cancer resistance protein
(BCRP), and multidrug resistance-associated proteins (MRP 1–
5) hydrolyzing ATP to actively pump drugs and their conjugates,
xenobiotics, endogenous metabolites, and nucleosides across the
luminal side of blood vessels into the circulation (Mahringer and
Fricker, 2016; Sweeney et al., 2019).
Selective peptides and even large proteins can enter the brain
by binding to receptors on endothelial cells via endocytosis
(receptor-mediated transcytosis) (leptin receptors, transferrin
receptors, and insulin receptors) (Preston et al., 2014). The
BBB is characterized by extremely low rates of vesicular
transport (transcytosis) which limits the transcellular passage
across CNS barriers. It has been recently reported that the
major facilitator superfamily domain containing 2a (Mfsd2a)
is selectively expressed in CNS blood vessels and actively
participates to BBB homeostasis by suppressing transcytosis
in CNS endothelial cells (Ben-Zvi et al., 2014). Mfsd2a is
located upstream of Caveolin-1 (Cav-1) (Chow and Gu,
2017), which is involved in regulating endothelial permeability,
angiogenesis, and leukocyte diapedesis (Zhao et al., 2014),
and VE-cadherin/catenin complex targets Cav-1 to endothelial
cell junctions leading to BBB breakdown under permeability
conditions (Kronstein et al., 2012).
These features exist within the majority of the CNS capillary
population. However, it is worth noting that some regions of the
CNS display a leaky BBB. These regions are grouped together
under the term “circumventricular organs” which are regions
of the brain sensing blood-borne signals. Morphologically, in
the circumventricular organs, the capillaries are fenestrated
with discontinuous tight junctions and thinner endothelial
cells which contain more vesicles than capillaries of other
parts of the CNS (Coomber and Stewart, 1985). This permits
the two-way exchange of metabolic information: the delivery
of neuro-hormones into the bloodstream by secretory organs
and the sensing of blood-borne molecules by neurons in
sensory organs. However, within the circumventricular organs,
there is no direct passage of blood-borne substances in the
parenchyma due to the presence of outer basement membrane
but also astrocytes and tanycytes (ependymal cells sharing
common features with radial glial cells and astrocytes) which are
considered alternative CNS barriers (Langlet et al., 2013). The
peculiar organization of the BBB within the circumventricular
organs leads us to approach the CNS vascular barrier system
from another angle by acknowledging its complex architecture
which is not just a vascular endothelium. Indeed, it is more
proper to consider it as a multi-cellular neurovascular unit
comprising notably astrocytes, pericytes, basement membranes
as well as blood vessels.
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FIGURE 1 | Healthy and tumor brain vascular architecture: focus on artery, arteriole, and capillary. Left panel: in a healthy brain vasculature, endothelial cell
monolayer is surrounded by a smooth muscle coat in arteries and arterioles, and is replaced by pericytes in the capillaries. The perivascular space is delimited by the
vascular basement membrane and glial basement membrane. This space gradually diminished and the two basement membranes enter in direct contact to
astrocytes endfeet. Molecules diffuse or are transported at the capillary level. Right panel: GBM is a highly angiogenic and infiltrative tumor. Cells invade along blood
vessels to support tumor growth (co-option). GBM displaces astrocytes endfeet and alters pericyte stability, leading to perivascular niches and cell evasion. Created
with Biorender.com.
THE NEUROVASCULAR UNIT, A
MULTI-CELLULAR CNS-BARRIER
STRUCTURE
A wealth of literature published during the last decades has
enabled a change in the vision of the BBB, leading to the
concept of a multi-cellular CNS-barrier structure. Indeed,
substantial intercellular communication occurs between vascular
cells (endothelial cells and pericytes) and the adjoining glia
(Iadecola, 2017). More specifically, to enter the CNS from the
vasculature, soluble factors and immune cells must traverse the
endothelial BBB and the adjacent pericyte layer. Once soluble
factors and immune cells penetrate the BBB, they circulate within
the perivascular space, a region surrounding the basal surface of
the endothelial cell wall, to reach the CNS parenchyma by passing
through the glia limitans composed of the parenchymal basement
membrane and the astrocyte endfeet (Engelhardt and Coisne,
2011; Engelhardt and Ransohoff, 2012).
Pericytes
Pericytes, strategically positioned along capillaries, play a
critical role in the multi-cellular CNS barrier structure. Indeed,
pericytes, sandwiched between endothelial cells and astrocytes,
are dynamically and synergistically engaged in interactions
with neighboring cells to maintain homeostasis of the CNS
(Figure 1 – healthy brain). Pericytes are notably involved in the
regulation of cerebral blood flow, neurovascular coupling and
BBB homeostasis.
A role for pericytes in the regulation of microcirculatory
blood flow has long been suspected (Armulik et al., 2011; Hall
et al., 2014; Sweeney et al., 2016). Recent work demonstrated
that pericytes synchronize microvascular blood flow dynamics
and neurovascular coupling via nanotube-like processes called
inter-pericyte tunneling nanotubes (IP-TNTs) which connect
two pericytes on separate capillaries to form a functional
network (Alarcon-Martinez et al., 2020). Pericytes are also
part of the neurovascular unit and are most firmly attached
to brain capillaries. They are involved in a crosstalk between
endothelial cells and the surrounding cerebral tissue. Notably,
it has been reported that pericytes interact with endothelial
cells via specific adhesion sites that represent peg-and-socket
junctions in the presence of N-cadherin (Sweeney et al., 2016),
the single cell adhesion receptor CD146 (Chen et al., 2017),
adhesion plaques containing fibronectin (Courtoy and Boyles,
1983), Connexin43 gap junctions (Cuevas et al., 1984), and
even tight junctions (Larson et al., 1987). In a mouse model
lacking pericyte coverage at the microvascular level, BBB integrity
is compromised because of the transcellular barrier specific
dysfunction (Sweeney et al., 2016) but also because of the loss
of astrocytic endfeet polarization (Armulik et al., 2010). While
pericytes are necessary for maintaining BBB integrity, astrocytic
endfeets are also major actors in CNS barrier homeostasis.
Astrocytes
Astrocytes represent an important population of glial cells
in the CNS and astrocytic endfeet create a thick continuous
layer that covers BBB microvessels called the glia limitans
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(Mathiisen et al., 2010) (Figure 1 – healthy brain). Neural
precursor cells represent the primary source of astrocytes
which develop at late gestation stages in mammals (Daneman
et al., 2010b; Cheslow and Alvarez, 2016). Therefore, it is
commonly accepted that if astrocytes do not play a major role
in BBB establishment, they strongly impact BBB maturation
and maintenance.
Reducing the vascular coverage of the population of astrocytes
and astrocytic endfeet in the early postnatal cerebral cortex
leads to the formation of microvessels with an abnormally
large diameter (Ma et al., 2012). In addition, astrocytes are
actively involved in the production of the basement membrane
embedding the glia limitans. Knocking down elements of the
basement membrane results in the disruption of Aquaporin4
(AQP4) channel enrichment at the astrocytic endfeet membrane
(Brightman, 2002; Lien et al., 2012; Menezes et al., 2014).
This leads to BBB permeability and associated brain edema
(Nagelhus and Ottersen, 2013).
Astrocytes maintain BBB integrity via the secretion of soluble
factors. Astrocytes improve endothelial barrier function in co-
culture or after administration of conditioned medium to CNS
endothelial mono-culture (Igarashi et al., 1999; Alvarez et al.,
2011; Podjaski et al., 2015). Astrocytes secrete soluble factors
notably Sonic Hedgehog (Shh) (Alvarez et al., 2011), retinoic
acid (RA) (Mizee et al., 2014), glial-derived neurotrophic factor
(GDNF) (Igarashi et al., 1999), and angiopoietin 1 (Ang-1) (Suri
et al., 1996; Pfaff et al., 2006) which reduce permeability.
Blood–brain barrier integrity in the cerebellum, spinal cord,
and olfactory bulbs relies on astrocyte-derived Wnt-like ligand
Norrin which interacts with the endothelial Frizzled4 receptor.
Knocking down the Norrin/Frizzled4 signaling leads to BBB
defects through β-catenin–dependent transcriptional regulation
(Zhou et al., 2014).
Astrocytes also express members of the ephrin receptor
(EphR)/ephrin family (Nestor et al., 2007) which may impact
BBB homeostasis. Notably, EphA4 receptor is expressed by glial
cells especially around blood vessels in the adult marmoset
(Goldshmit et al., 2014). EphA4 also plays a role in vascular
formation and guidance during CNS development in mice. The
proper interaction between the EphA4 receptor and its astrocytic
ephrinA5 ligand is necessary for the development of a normal
vascular system in the hippocampus of adult mice (Goldshmit
et al., 2006; Hara et al., 2010).
Hence, based on these strong arguments, it is now recognized
that the vascular component in the CNS is inseparably linked to
glial and neuronal partners. Therefore, it is necessary to consider
the neurovascular unit as a whole (and not only the BBB) in
vascular pathophysiology and targeted therapeutic strategies.
Glioblastoma Disrupts The Normal Brain
Architecture And Molecular Interactions
Basic Characteristics of Glioblastoma
Diffuse gliomas are brain tumors classified into IDH1mut
and WT tumors (Louis et al., 2016). Glioblastomas (grade IV
gliomas) are generally IDH WT tumors and represent the most
aggressive form with an extremely poor prognosis. It is now
admitted that glioblastoma (GBM) are mainly derived from
neural stem cells, giving rise to transformed cells with astrocytic,
neuronal, or oligodendrocytic characteristics (Alcantara Llaguno
et al., 2009; Zong et al., 2012). Accumulation of genetic
mutations, alterations, and amplifications play a central role
in the transformation of healthy neural stem cells. Typical
alterations in primary GBM are represented by amplification
or mutation of PTEN, NF1, CDKN2A/B, and RB genes, or
homozygous deletion or mutation of MDM2, CDK4, EGFR,
PDGFRα, and PI3K genes. Typical histopathological features
of GBM comprise highly proliferative cells with multinuclei,
areas of necrosis surrounded by pseudopalisading cells, and
endothelial cell proliferation with numerous clusters of blood
vessels forming so-called glomeruloid structures. In 1938,
Scherer highlighted several modes of GBM invasion: interstitial
invasion, white matter tract invasion, and perivascular invasion
(Scherer, 1940). GBM invasion relies on genetic alterations
such as overexpression, amplification, deletion, or mutation
in focal adhesion kinase (FAK) and phosphatidylinositol 3-
kinase (PI3K) pathways. Activation of growth factors and their
receptors are mainly involved in promoting invasion. These
include CD44, integrins, osteonectin (SPARC), transforming
growth factor (TGF)α/β, and receptors for platelet-derived
growth factor (PDGF), fibroblast growth factor (FGF-2), and
epidermal growth factor (EGF). Extracellular matrix components
such as thrombospondins, laminins, or fibronectin are also
overexpressed in GBM and their inhibition reduces invasiveness
of GBM cells (Serres et al., 2014; Chouleur et al., 2020). Indeed, we
and others characterized the role of thrombospondin-1 (which
was primarily described as anti-angiogenic molecule) in GBM
development and invasion (Daubon et al., 2019).
Glioblastoma is the most common brain tumor in Europe,
in the United States, or in China, with more than 50% of
glioma cases each year, and with an incidence of 3.2 per 100,000
people each year in the United States. Increasing incidence in
populations from several countries were observed, suggested by
authors as consequences of environmental or lifestyle factors
(Philips et al., 2018). The 5-year overall survival (OS) rate is
very low of only 5.1%, even with standard-of-care treatment
(large tumor resection, chemo- and radiotherapy, so-called Stupp
protocol). GBM are often only diagnosed at an advanced stage
of the disease and often only detected when patients present
symptoms (headaches, seizures, memory loss, loss of movements,
cognitive impairments, and language dysfunctions). The poor
response to therapy is partially explained by high intratumor
heterogeneity, leaky and tortuous blood vessels in the central
part, and intact BBB surrounding invasive cells, which leads
to difficulties for therapeutic molecules to reach these sites
(Figure 1 – glioblastoma).
Metabolic Interactions Between GBM
Cells and the Endothelium
Glioblastoma is considered as one of the most glycolytic human
tumors. High glycolytic flux drive production of pyruvate from
glucose, and then pyruvate into lactate by lactate dehydrogenases,
to regenerate NAD+ to support glycolytic flux by fulfilling the
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demand for ATP and other metabolic precursors. As previously
described in striated muscles and also in the brain, lactate is,
in turn, retro-converted into pyruvate by oxygenated tumor
cells to feed oxidative metabolism. This phenomenon was
described in the seminal publication of Pellerin et al. (1998)
as lactate shuttle between astrocytes and neurons. Vegran et al.
(2011) also demonstrated a lactate shuttle between tumor cells
and endothelial cells, mainly via endothelial monocarboxylate
transporter 1 (MCT1). More recently, MCT1 was also identified
as a key mediator of lactate signaling between glioma cells
and brain endothelial cells (Miranda-Gonçalves et al., 2017).
Targeting symbiotic metabolism between GBM and endothelial
cells may represent an interesting therapeutic strategy.
Involvement of Pericytes and Astrocytes
in Glioblastoma Vascular
Pathophysiology
The chronic hyper-permeability of blood vessels is a hallmark
of glioblastoma. We focus herein our attention on the role of
pericytes and astrocytes in disrupting the BBB in glioblastoma.
Role of Pericytes
Glioblastoma vessels are characterized by numerous structural
and functional abnormalities, including altered association
between endothelial cells and pericytes. These dysfunctional,
unstable vessels contribute to hypoxia, interstitial fluid pressure,
and enhanced susceptibility to metastatic invasion (Barlow
et al., 2013). An interesting feature of glioblastoma pericytes
is that they represent one of the active cell components of
the perivascular niche. It has been reported that cancer stem
cells, which are closely associated with tumor vessels, trans-
differentiate into endothelial cells or pericytes (Wang et al., 2010;
Cheng et al., 2013), a phenomenon described as vasculogenic
mimicry (VM). VM was also shown to be promoted by tumor-
associated macrophages (TAMs) by increasing the expression
of cyclooxygenase 2 in the tumor cells (Rong et al., 2016) and
has been associated with poor patient prognosis. However, the
significance of VM in GBM is still debated and not universally
accepted. Furthermore, tumor-derived pericytes exhibit specific
genetic alterations that allow for discrimination between them
and normal pericytes (Cheng et al., 2013), which may be
relevant for diagnosis and therapy. Finally, pericytes were shown
to promote evasion from the anti-tumor immune response
favoring tumor growth (Figure 1 – glioblastoma). Glioblastoma-
dependent immunosuppressive function in pericytes is mediated
by the expression of anti-inflammatory molecules such as IL-10,
TGF-β, and MHC-II (Valdor et al., 2017).
Role of Astrocytes
Reactive astrocytes are an integral part of the glioblastoma micro-
environment and are characterized by hypertrophy, upregulation
of intermediate filaments (vimentin and glial fibrillary acidic
protein), and increase in proliferation. The role of reactive
astrocytes in the pathophysiology of glioblastoma has been
widely documented in the literature. Astrocyte–glioma crosstalk
was shown to drive migration, proliferation, and invasion of
glioblastoma (Guan et al., 2018). However, only few works
focused on the contribution of astrocytes to the aberrant
organization of the BBB in these tumors.
The participation of astrocytes to BBB permeability in
glioblastoma is documented by the loss of astrocytic endfeet
polarity which is characterized by Aquaporin-4 (AQP4)
redistribution to membrane domains apart from endfeet areas
(Kröger et al., 2004). This re-localization is probably due
to the degradation of the proteoglycan agrin by the matrix
metalloproteinase 3 (MMP3). Consequently, the water transport
is compromised leading to edema. This, in turn, may drive BBB
breakdown characterized by disrupted tight junctions leading
to the development of vasogenic edema. However, how the
loss of polarity is linked to the disturbance of microvascular
tight junctions is still not understood (Wolburg et al., 2012).
Using a clinically relevant mouse model of glioblastoma, it
has been shown that tumor cells populate the perivascular
space of preexisting vessels and displace astrocytic endfeet
from endothelial or mural cells. This leads to abnormal BBB
permeability and loss of astrocyte-mediated gliovascular coupling
which pave the way for glioma cells to take control of vascular
tone regulation (Watkins et al., 2014). This phenomenon, known
as blood vessel co-option, is a strategy for glioblastoma to invade
distant sites of the brain parenchyma (Figure 1 – glioblastoma).
Vessel co-opting GBM cells directly obtain oxygen and nutrients
from the blood. The interactions with the vascular niche
stimulate proliferation and self-renewal of GBM cells.
There is still much to explore as reactive astrocytes have
already been identified as key players impacting the state of the
BBB in various diseases (Liebner et al., 2018). They are likely to
also play an important role in vessel hyper-permeability of GBM.
VASCULAR TISSUE ENGINEERING AND
ITS POTENTIAL FOR THE STUDY OF
GBM–VESSEL INTERACTIONS
The tumor vasculature is critically involved in GBM
development. This has led to clinical trials using anti-angiogenic
drugs but with mixed results (Chinot et al., 2014). It has been
postulated that anti-angiogenic treatment may impact tumor
cell behavior by shifting them from an angiogenic to a co-
optive behavior (Griveau et al., 2018). Thus, it is important to
better understand more rigorously how tumor cells and vessels
interact. A number of experimental models have been proposed
in this context.
There are two classic and widely used models to study the
role of the vasculature in tumor growth: the in vivo chick chorio-
allantoic membrane (CAM) assay (Lokman et al., 2012) and the
in vivo mouse/rodent graft model (Eklund et al., 2013). These two
models are based on grafting tumor cells on the membrane of a
growing chicken or in a specific site in mouse. If the chick model
follows to some extent better the 3R rule (replacement, reduction,
and refinement; Aske and Waugh, 2017) as considered as less
sentient living beings due to not fully active nervous system, it
is nevertheless necessary to develop alternative models that are
closer to the human situation.
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During the last decade, tissue engineering led to the
development of artificial vessels which can be used for tissue
vascularization in a 3D environment. These in vitro models may
represent a promising alternative to animal models.
Regarding studies related to tumor–vessel interactions, it
is important to note that cancer cells are involved in two
phenomena: inducing vessel sprouting (angiogenesis) and
transmigrating through the blood vessel wall (endothelial cells,
smooth muscle cells, and matrix) for dissemination. The
latter phenomenon is difficult to study in both CAM and
mouse models. It is therefore necessary to develop in vitro
models that are closer to the human situation. During the last
decade, tissue engineering led to the development of artificial
human vessels which can be used for tissue vascularization
in a 3D environment. These in vitro models, which harbor
all the histological components of a blood vessel (lumen,
endothelium, smooth muscle cells, and matrix), must also retain
its mechanical properties such as liquid-tightness, perfusability,
and contractility.
Tissue-Engineered Blood Vessels
Since the 1950s, synthetic tubes were the first choice for
vascular reconstruction and grafts in patients with cardiovascular
diseases. These conducts were made of polymer materials
like expanded polytetrafluoroethylene (ePTFE), polyethylene
terephthalate (Dacron), and polyurethane (Kannan et al., 2005),
but all the functional characteristics of a blood vessel were
not maintained in these tubes: they were not contractile and
are not immune to thrombosis or inflammation. Motivated
by these limitations, the development of 3D tissue-engineered
blood vessels (TEBVs) has progressed significantly over the
past two decades. Indeed, TEBVs tend to better match the
biomechanical properties and the physiological responses of
healthy blood vessels.
Tissue-engineered blood vessels can be not only used for
vascular grafts but also for mechanistical studies related to the
tumor–vessel interaction. For all the aforementioned reasons,
engineering of artificial blood vessels is not an easy task and has
been for a long time restricted to big diameter arteries (>6 mm)
(Niu et al., 2014), and were usually made of synthetic polymers
without endothelial of smooth muscle cell. Recently, efforts have
been made to produce smaller blood vessels (<2 mm) by the use
of various approaches (Song et al., 2018) (Figure 2A).
The production of tubular structures is achieved by three
commonly used techniques: sheet rolling, tubular molding, and
direct scaffolding. The sheet rolling technique is based on the
creation of a sheet with the biomaterial of your choice and on
the rolling of several sheets together for generating a tubular
structure (Peck et al., 2011). Weinberg and Bell (1986) first
described the use of a tubular mold that was filled with the
desired cells and matrix. Finally, most of the biopolymers can be
directly injected in a tubular form by direct scaffolding, but the
major issue for all these techniques is the long-term culture of
blood vessel. As an example, two pioneered groups (Roger Kamn
and Lance Munn) developed in 2011 and 2012 microfluidic
channels surrounded by 3D hydrogels using microfabricated
silicone molds (Song and Munn, 2011; Shin et al., 2012). The
point was to put endothelial cells in 2D culture on top of these
hydrogels to mimic vessel sprouting and invasion inside a tissue.
These models were subsequently improved by mixing stroma
and tumor cells inside the hydrogel for tumor angiogenesis
studies. A recent paper by Andrique et al. (2019) used a co-
extrusion microfluidic device to produce small-diameter artificial
vessels (<500 µm) with both endothelial and smooth muscle
cells, surrounded by a scaffold made of biocompatible alginate
polymer. These “vesseloids” are rapidly formed (only 1 day
of culture) easy to handle, perfusable, liquid-tight, and retain
their vascular functions (contractility, response to inflammatory
stimuli) (Figure 2B). Vesseloids may be used as trunks for
angiogenic sprouts to emerge which are useful for organ or tumor
vascularization.
Controlled Microenvironment in 3D
in vitro Models
3D co-culture systems including tumors cells, endothelial cells
(blood vessels), and other micro-environmental components
have emerged for reproducing tumor–stroma interactions. It
was shown that tissue stiffness modulate tumor growth and
nutrient transport (Massa et al., 2017). This is critical and
must be considered for drug testing in cancer therapy. The
major advantage of 3D co-culture models relies on the fact that
various parameters can be controlled: type and density of the
ECM components (e.g., Matrigel, collagen, PEG, fibronectin,
and gelatin methacryloyl), stiffness, hypoxia and gas exchange,
and the inclusion of various cell types such as macrophages,
astrocytes, or vascular cells.
3D systems, which do not include the vascular component,
already improve phenotypic properties, gene expression, and
drug response. The importance of the environment in drug
delivery testing was already highlighted by Seo et al. (2014).
They explained that new anti-cancer drugs are usually tested
in 2D tissue culture which neglects the complexity of the 3D
micro-environment (Langhans, 2018). The development of 3D
in vitro tissue-engineered models will help to refine the drug
response and contribute to the improvement of anti-cancer
therapies. More recently, striking differences in gene expression
between 2D and 3D culture of GBM have been reported (Ma
et al., 2018) which mirrored the phenotypic differences. This
is in agreement with another study (Chaicharoenaudomrung
et al., 2020) where GBM cells were cultured in Ca-alginate
3D scaffolds before next-generation sequencing (Illumina), and
this uncovered cellular pathways (Map kinase, autophagy, and
cell metabolism) for 3D different to 2D cultures. Musah-
Eroje and Watson (2019) developed a new 3D model of
GBM which seems to more accurately reflect the complexity
of the GBM micro-environment. Compared with regular
2D cultures or spheroids, they showed that GBM cells in
the3D model were more resistant to temozolomide and that
this resistance was potentiated by hypoxia. One unresolved
issue regarding 3D brain organoid models is the lack of
functional vascularization. Recently, Cakir et al. (2019) developed
with success in vitro functional vasculature-like networks in
human cortical organoids (hCOs) from human embryonic
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FIGURE 2 | Vascular models in neuro-oncology research. (A) Fabrication strategies for engineering artificial vessels. Vascular models are synthesized by rolling,
molding, scaffolding, or microfluidic co-extrusion using biomaterials with/without cells. Addition of glioblastoma cells creates a vascularized tumor model.
(B) Confocal imaging of vesseloid (scale bar: 50 µm). Nuclei in blue (DAPI), αSMA in green, and endothelial marker in red (CD31). On top and merge panels, images
correspond to a maximal intensity projection along the z-axis. Other panels are 3D-image reconstructions.
stem cells (hESCs). In this work, endothelial reprogramming
in hCOs induced the formation of organoids with vascular-
like structures. These vascular structures are functional and
exhibit BBB characteristics. Close to this work, a recent
model of vascularized human cortical organoids (vOrganoids)
was developed by Shi et al. (2020) (Vascularized human
cortical organoids (vOrganoids) model cortical development
in vivo 2020 PLOS One). These vOrganoids (human cortical
cell types with vasculature structure) presented bidirectional
electrical transmission trough functional synapses, and their
transplantation in the mouse cortex resulted in the survival of the
graft. All these innovative 3D models represent useful models for
studies related to physiology or pathology and may be useful as a
model for therapeutic studies.
3D Co-Culture Models of Tumor and
Endothelial Cells
The ultimate step of these 3D tumor models is the inclusion
of endothelial and/or pericytes/smooth muscle cells to mimic
blood vessels to produce vascularized tissues. A number of these
works were done in tumor types other than glioblastoma. For
example, Silvestri et al. (2020) developed a tissue-engineered
model of a 3D co-culture of microvessels and mammary tumor
organoids. They first fabricated a collagen gel scaffold with
cylindrical channels filled with endothelial cells as a microvessel
device. After perfusion and verification of the microvessels
permeability, mammary tumor organoids were introduced
inside of the 3D collagen scaffold and tumor cell–endothelial
cell interactions were analyzed by live imaging. Others went
further and developed a tri-culture metastatic model of breast
cancer (Cui et al., 2020). By stereolithography 3D printing,
a complex tripartite tissue was created which is composed of
bone, vessels, and breast cancer cells. This model was used to
study mechanisms of bone metastasis. Wang et al. (2014) have
developed a 3D model to observe tumor invasion with high
spatial and temporal resolution. Furthermore, intravasation and
extravasation were observed at high spatial resolution using
microvessels embedded in collagen 3D matrix and mixed with
cancer cells (Langhans, 2018). As for glioblastoma, McCoy et al.
(2019) generated GBM spheroids of uniform size distribution,
and embedded them into collagen hydrogels to investigate GBM
invasion into the ECM of the perivascular niche. They also
showed by co-culturing endothelial and GBM cells that GBM
cells have a high stemness potential and invasion capacity
dependent on IL-8 signaling. Thus, tumor vasculature models
may be very useful to shed light into the complex interactions
between the vasculature and tumor cells.
REVIVAL OF ANTI-ANGIOGENIC
THERAPY: COMBINATION WITH OTHER
DRUGS
Anti-Angiogenic Background
To date, bevacizumab is the only anti-angiogenic drug admitted
for GBM management. Based on the results of three different
clinical studies (Table 1), bevacizumab was approved by the
Food and Drug Administration (FDA), the Japanese Ministry
of Health, Labour and Welfare (MHLW), and other countries
as a combination treatment with standard therapy and as a
single agent for relapsed or progressive GBM after previous
therapy. However, the OS was not prolongated in these studies;
bevacizumab showed nevertheless some benefit in decreasing the
use of corticosteroids, the adverse effects of which impair patient’s
quality of life. However, the European Medicine Agency (EMA)
has not approved its indication, estimating that the benefit–risk
assessment is not in favor of its prescription in the management
of GBM. This is also supported by the National Institute for
Health and Care Excellence (NICE) guidelines (NICE, 2018). It
is important to emphasize that bevacizumab cannot be used a
month before and after brain surgery. This must be considered
when using this treatment. Of note, the pharmacokinetics and
bioavailability of bevacizumab is limited since it cannot cross the
intact BBB which is nevertheless partially disrupted to allow drug
penetration to some extent.
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TABLE 1 | Pivotal clinical trials supporting the approval indication.











Phase III (N = 921)
(1) RT + TMZ + Placebo
(N = 463)
(2) RT + TMZ + Bev
(N = 458)
*6.2 (6.0–7.5) vs. 10.6
(10.0–11.4) months;




months; HR = 0.88







Phase III (N = 637)
(1) RT + TMZ + Placebo
(N = 317)
(2) RT + TMZ + Bev
(N = 320)
*7.3 (5.6–7.9) vs. 10.7
(10.0–12.2) months;




months; HR = 1.13






Phase III (N = 437)
(1) Lomustine alone
(N = 149)
(2) Lomustine + Bev
(N = 288)
#1.5 (1.5–2.5) vs. 4.2
(3.7–4.3) months;
HR = 0.49 (0.39–0.61);
p < 0.001
*8.6 (7.6–10.4) vs. 9.1
(8.1–10.1) months;
HR = 0.95 (0.74–1.21);
p = 0.65
RT, radiotherapy; TMZ, temozolomide; Bev, bevacizumab; PFS, progression-free survival; OS, overall survival. ∗Primary outcome measure. #Secondary outcome measure.
Revival of Bevacizumab and
Anti-Angiogenic Therapy
Bevacizumab alone is certainly not a curative treatment for
GBM and this raises ethical issues related to the benefit–risk
of this treatment between the improvement of the patients’
quality of life and frequent occurrence of serious side effects.
Security data of clinical trials, as pharmacovigilance studies, have
shown frequent and serious cardiovascular effects (hemorrhages,
thromboembolic events, and heart failure) and hematological
disorders (neutropenia, leukopenia, and thrombocytopenia)
(Chinot et al., 2014; Gilbert et al., 2014; Wick et al.,
2017). On theoretical grounds, the use of anti-angiogenic
drugs may be justified due to physiopathological consideration
(high expression of VEGF, BBB dysfunction, edema leading
to hemorrhages, cognitive impairment, tumor growth, and
cell invasion). Better outcomes may be observed when anti-
angiogenic therapy is combined with inhibitors of tumor cell
invasion or in combination with immunotherapy as documented
in some studies (Kang et al., 2015; Piao et al., 2016; Gravina et al.,
2017; Daubon et al., 2019).
A short review of the last-5-years published clinical trials is
shown in Table 2, using the following parameters from PubMed:
key words = Glioblastoma AND Antiangiogenic; filters = Abstract
available, Clinical Trial; date = between 2015 and 2020. As
no clinical trials of phase III were found, articles related to
phase II studies, describing new associations or new indications
with bevacizumab or new individual anti-angiogenic drugs,
were selected if median progression-free survival (mPFS) or the
median overall survival (mOS) outcomes were available and if
the trial was referenced in https://clinicaltrials.gov/. mPFS and
mOS reflect more robust outcomes than response rate. Eighteen
clinical trials were found using these inclusion criteria.
New Investigations for Bevacizumab
Certain populations are under-represented in global clinical
trials. This has led to the investigation of the efficacy
of bevacizumab in newly diagnosed GBM (nGBM) in
the elderly (ARTE, Wirsching et al., 2018 and ATAG,
Reyes-Botero et al., 2018 studies) and in pediatric populations
(HERBY study, Grill et al., 2018). The ARTE study showed
that when radiotherapy associated with bevacizumab, it did
not prolong mOS compared with radiotherapy only (12.2 vs
12.1 months; HR = 1.09; p = 0.75). However, mPFS was favorable
with bevacizumab in restricted per protocol analyses (7.6 vs
4.8 months; HR = 0.36; p = 0.001) (Wirsching et al., 2018). In
combination with temozolomide, bevacizumab seemed active
in the ATAG study and had an acceptable adverse effect profile
(Reyes-Botero et al., 2018). As for the pediatric population,
adjunction of bevacizumab to the current therapy did not
improve mOS (18.3 vs 20.3 months; HR = 1.23; p = 0.46) (Grill
et al., 2018). The results in the pediatric population differ from
adults, and, thus, further research is needed.
New Associations With Bevacizumab
Glioblastomas are associated with increased stimulation
of different signaling pathways. Trials have been run with
bevacizumab combined with molecules interfering with these
pathways. The association of bevacizumab with BKM 120–
buparlisib, an oral PI3K inhibitor, did not improve outcome
(mPFS: 2.8 to 5.3 months; mOS: 6.6 to 10.8 months) and
increased the adverse drug effect profile (Hainsworth et al.,
2019). In another study, mOS in the arm of bevacizumab
combined with dasatinib, a Src signaling inhibitor, is similar
to the placebo arm (7.3 vs 7.9 months; HR = 0.92; p = 0.7)
(Galanis et al., 2019). In two trials, addition with bevacizumab
to the histone deacetylase inhibitors vorinostat (Ghiaseddin
et al., 2018) and panobinostat (Lee et al., 2015) failed to
improve outcome compared with control (mPFS: 3.7 and
5 months; mOS: 10.4 and 9 months, respectively). When
bevacizumab is combined with onartuzumab, a monovalent
MET inhibitor, it did also not improve patient outcome
versus bevacizumab plus placebo alone (mPFS: 3.9 vs
2.9 months; HR = 1.06; p = 0.74 and mOS: 8.8 vs 12.6 months;
HR = 1.45; p = 0.14) (Cloughesy et al., 2017). The GLARIUS
trial aimed to study the association of bevacizumab with
irinotecan, a topoisomerase 1 inhibitor, comparing with
temozolomide alone in nGBM with un-methylated MGMT
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TABLE 2 | Phase II clinical trials recently published.










open label (N = 76)
BKM 120 (buparlisib)
per os + Bev
(1) Prior anti-angiogenic
















open label (N = 33)
(1) Dovitinib per os in
anti-angiogenic naïve
patients (N = 19)













blinded (N = 12(1)
(1) Bev + dasatinib per
os (N = 83)
(2) Bev + placebo
(N = 38)
#(1) 7.3 (6.2–9.7) vs.
(2) 7.9 (6.6–11.3);










(1) Regorafenib per os
(N = 59)
(2) Lomustine per os
(N = 60)
*(1) 7.4 (5.8–12.0) vs (2)
5.6 (4.7–7.3); HR = 0.5
(0.33–0.75); p = 0.0009
ARTE (NCT01443676)






(1) RT (N = 25)
(2) RT + Bev (N = 50)
#(1) 4.8 vs (2) 7.6;
HR = 0.36 (0.20–0.65);
p = 0.001
*(1) 12.1 vs (2) 12.2;












open label (N = 66)










(1) RT + TMZ (N = 59)
(2) RT + TMZ + Bev
(N = 62)
#(1) 20.3 (14.8–33.8)
vs. (2) 18.3 (16.2–25.7);




(Reardon et al., 2018)
Recurrent GBM Randomized, parallel
assignment, double
blinded (N = 115)
(1) Bev + placebo
(N = 58)
(2) Bev + trebananib
(N = 57)
#(1) 4.8 (3.8–7.1) vs. (2)
4.2 (3.7–5.6);
HR = 1.51 (1.02–2.24);
p = 0.04
#(1) 11.5 (8.4–14.2) vs
(2) 7.5 (6.8–10.1);





Recurrent GBM Non-randomized, single
group assignment,
open label (N = 40)
Bev + vorinostat
(N = 40)
#3.7 (2.9–4.8) #10.4 (7.6–12.8)
NCT00704288







open label (N = 222)
Cabozantinib per os
(N = 70)
(1) 140 mg/day (N = 12)
(2) 100 mg/day (N = 58)
#2.3 overall
(1) 3.3– 2) 2.3
#4.6 (3.0–5.6) overall









open label (N = 222)
Cabozantinib per os
(N = 152)
(1) 140 mg/day (N = 34)
(2) 100 mg/day
(N = 118)




(Cloughesy et al., 2017)
Recurrent GBM Randomized, parallel
assignment, double
blinded (N = 129)
(1) Bev + onartuzumab
(N = 64)
(2) Bev + placebo
(N = 65)
*(1) 3.9 vs. (2) 2.9;
HR = 1.06 (0.72–1.56);
p = 0.74
#(1) 8.8 vs. (2) 12.6;





Recurrent GBM Non-randomized, single
group assignment,
open label (N = 10)
Tivozanib #2.3 (1.5–4) #8.1 (5.2–12.5)
(Continued)
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TABLE 2 | Continued
Study name or ID Indication Design Treatment arms Outcomes (months)
mPFS mOS
NCT01067469
(Weathers et al., 2016)
Recurrent GBM Randomized, single
group assignment,
open label (N = 69)

















(1) Bev + irinotecan
(N = 122)
(2) TMZ (N = 60)
#(1) 9.7 (8.7–10.8) vs.
(2) 6.0 (2.7–6.2);
HR = 0.59 (0.42–0.82);
p = 0.001
#(1) 16.6 (15.4–18.4)
vs. (2) 17.3 (14.8–20.4);
HR = 0.96 (0.68–1.35);
p = 0.83
NCT00667394 Recurrent GBM Non-randomized,
parallel assignment,
open label (N = 41)










Bev + erlotinib ¤9.2 (6.4–11.3) *13.2 (10.8–19.6)
NCT00859222 (Lee
et al., 2015)
Recurrent GBM Non-randomized, single
group assignment,
open label (N = 24)
Bev + panobinostat #5 (3–9) #9 (6–19)
mPFS, median progression-free survival; mOS, median overall survival; Bev, bevacizumab; RT, radiotherapy; TMZ, temozolomide.
*Primary outcome measure. #Secondary outcome measure. ¤Post hoc analysis.
promoter. This resulted in a superior mPFS with the drug
combination (9.7 vs 6.0 months; HR = 0.59; p = 0.001) without
improving mOS (16.6 vs 17.3 months; HR = 0.96; p = 0.83)
(Herrlinger et al., 2016).
Another strategy aims at an additive effect by targeting both
the vasculature and tumor cells and by combining bevacizumab
with inhibitors of other growth factor pathways. Trebananib
is a Fc fusion protein that targets Ang1 and Ang2; however,
its association with bevacizumab failed to improve outcome
when compared with bevacizumab plus placebo alone (mPFS:
4.2 vs 4.8 months, HR = 1.51, p = 0.04; and mOS 7.5 vs
11.5 months, HR = 1.46, p = 0.09) (Reardon et al., 2018).
The association between bevacizumab and tandutinib, an oral
FLT3, c-Kit, and PGDFRβ inhibitor, showed some benefit
(post hoc mPFS: 4.1 months; post hoc mOS: 11 months) but
showed a high toxicity (Odia et al., 2016). One trial with
patients presenting a nGBM with an unmethylated MGMT
promoter investigated the combination with erlotinib, an EGFR
tyrosine kinase inhibitor. This association did not also increase
survival (mOS: 13.2 months – estimated mOS should have
reached 17.9 months to show an increase in survival) (Raizer
et al., 2016). This indicates that, during these last 5 years, no
new drug combination with bevacizumab showed substantial
clinical benefit and even increased toxicity. Furthermore, when
comparing the use of low doses of bevacizumab to standard doses
in patients with rGBM, it did not improve survival (mPFS: 4.34
vs 4.11 months; mOS: 9.6 vs 8.3 months) (Weathers et al., 2016).
Combination with immunotherapy also did not provide
significant benefit. Recently nivolumab was investigated in a
phase III randomized clinical trial with or without bevacizumab
in patients with rGBM; nivolumab arm did not improve mOS
[9.8 (8.2–11.8) vs 10.0 (9.0–11.8) months; HR = 1.04 (0.83–
1.30), p = 0.76] and showed a lower mPFS [1.5 (1.5–1.6)
vs 3.5 (2.9–4.6) months; HR = 1.97 (1.57–2.48), p > 0.001]
(Reardon et al., 2020).
New Anti-Angiogenic Drugs
Bevacizumab is the first representative of a drug family that
interfered with the VEGF pathway. Others are represented by
VEGF receptor tyrosine kinase inhibitors. A great advantage
of these drugs is the oral administration which increases the
patient’s observance. In 2013, a phase III clinical trial studied
the efficacy of cediranib, VEGFR, PDGFR, and c-Kit inhibitor, in
combination with lomustine versus lomustine alone in patients
with rGBM, but results did not show improvement of PFS
(Batchelor et al., 2013). In a trial that compared dovitinib,
a FGFR and VEGFR inhibitor, as second-line treatment after
prior anti-angiogenic therapy by bevacizumab, no efficacy in
prolonging mPFS (1.8 vs 2 months) was seen (Sharma et al.,
2019). Tivozanib also showed limited activity in rGBM (mPFS:
2.3 months; mOS: 8.1 months), but the patient number in the trial
(N = 10) was low (Kalpathy-Cramer et al., 2017). Two studies
on cabozantinib, which inhibits MET and VEGFR2, on a global
population did show some positive outcome in the rGBM group
not treated previously with anti-angiogenic drugs (mPFS: 2.3 and
3.7 months; mOS: 4.6 and 10.4 months) (Cloughesy et al., 2018;
Wen et al., 2018). Furthermore, the REGOMA study showed
encouraging therapeutic benefit with regorafenib compared with
lomustine alone (mOS: 7.4 vs 5.6 months; HR = 0.5; p < 0.001)
(Lombardi et al., 2019).
Drug Delivery
Therapy development for GBM is challenging. This is due to
resistances to radio- and chemotherapy because of the presence of
glioblastoma stem-like cells (Safa et al., 2015). Furthermore, the
CNS is composed of natural barriers which impair drug delivery
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into the brain. As such, the BBB allows the passive transport
of gas and liposoluble molecules. BBB’s tight junctions regulate,
furthermore, paracellular transport.
Current pharmacological treatments for GBM are
administered systemically by intravenous injection or orally.
Oral route simplifies patient treatment by proposing several
pharmaceutical options. Parenteral route allows a short action
period and a controlled dosage. However, tissue diffusion into
the brain is hampered and toxic side effects occur because
of their systemic action and the possibility to reach the brain
tissue only when the BBB is altered. To overcome these
problems, permeability of drugs can be enhanced by increasing
liposolubility or integrating them into liposomes or nanocarriers.
On the other hand, BBB can be temporarily disrupted by
therapeutic ultrasound whereas a hyperosmotic disruption
did not improve the drug penetration (Kobrinsky et al., 1999;
Idbaih et al., 2019).
Another possibility is to administer topically medicinal
products using injectable or implantable devices with sustained
drug release. Local delivery strategies aim at increasing the
concentration of the drug at the tumor site, at decreasing
alterations related to enzymatic metabolization, and at reducing
the systemic side effects. After surgery, the resection cavity
represents an accessible implantation site near non-surgically
resectable cells. The only approved strategy by the FDA for nGBM
and rGBM is the carmustine-impregnated biodegradable Gliadel
wafer. However, these implants did not improve outcomes
and presented higher local toxicity (brain edema, seizures) (De
Bonis et al., 2012). Hydrogels are a 3D matrix composed of a
hydrophilic polymer network. Injectable hydrogel is a reservoir-
system similar to soft tissue that can contain a large panel
of drugs able to diffuse into the surrounding tissue (Basso
et al., 2018). Antineoplastic drugs can be administered directly
into the cavity or in the cerebrospinal fluid via an intrathecal
injection device (Ommaya reservoir) for therapeutic delivery
(Ommaya, 1984). However, the drug concentration decreases as
the diffusion distance increases, and thus, this approach is of
limited use in highly infiltrating tumors. Moreover, long-term
use of these medical devices may cause complications including
infections and hemorrhages. Convection-enhanced delivery has
been developed to increase local delivery by enhancing diffusion
by a bulk flow to maintain a pressure gradient (Bobo et al.,
1994). Despite an acceptable safety profile, this method did
not improve clinical outcomes of patient with GBM (Oberoi
et al., 2016). An alternative method is the use of the intranasal
delivery, which is non-invasive because of the anatomical
proximity of these structures. Intranasal administration of a
telomerase inhibitor in a rat model extended animal survival
(Hashizume et al., 2008).
Perspectives for Anti-Angiogenic Drugs
There are new avenues to be explored for anti-vascular therapy.
They can be used to enhance the activity of other therapies.
For example, local hypoxia induced by bevacizumab could
activate evofosfamide, a hypoxia-activated alkylating prodrug
(Duan et al., 2008). Evofosmamide was studied on a phase
I clinical trial for the treatment of rGBM following previous
bevacizumab therapy, and results appeared to be favorable
for being studied in a phase II trial (Brenner et al., 2018).
Furthermore, anti-angiogenic therapy could be of more benefit
in some GBM subgroups. In a retrospective study of the
AVAglio Trial, it has been shown that bevacizumab treatment
led to a prolongation of OS of 4.3 months compared with
placebo (17.1 vs 12.8 months; multivariable HR = 0.42;
p = 0.001) in patients with proneural and IDH-1 wild-type
nGBM (Sandmann et al., 2015). To date, the use of anti-
angiogenic drugs should preferably be part of personalized
care for patients.
GENERAL CONCLUSION
The vasculature plays an important role in the brain in normal
and pathological conditions. In this article, we reviewed some
recent literature on this subject. In a healthy tissue, endothelial
cells are considered gatekeepers in all vessel types, for controlling
diffusion of soluble factors or immune cells, by using para-
or transcellular pathways. In GBM, however, vessels present
maturation defect and chronic hyper-permeability, leading to
vessel leakage, and poor vessel perfusion and delivery of
nutrients. Pericytes and astrocytes have a central role in
controlling physiology of normal and GBM NVUs. Pericytes,
which are positioned along capillaries, help GBM cells to
invade distant sites along blood vessels, as observed for reactive
astrocytes. Importantly, GBM cells displace the astrocytic endfeet
during co-option, disrupting endothelial cell junctions, and
participating in blood leakage and hemorrhage.
The tumor–vessel interaction can also be modeled using
in vitro bioengineered blood vessels. For now, no perfect 3D co-
culture model exists. However, recent efforts have been made
at developing 3D artificial vessels and 3D co-culture models
using co-cultures of cancer cells and artificial blood vessels.
Regarding vascularized 3D GBM models, researchers departed
from 2D co-cultures to spheroids and are now able to reproduce
small brain organoids with or without a functional vascular
network. The main challenge for brain organoids is the co-
culture of multiple cell types including neurons, astrocytes,
oligodendrocytes, and microglia (Cakir et al., 2019). Another
difficulty is the reconstruction of a tissue resembling to the
human brain with microglia and six cortical layers (Heide
et al., 2018) which exhibits the functional characteristics of
the human brain such as neuronal networks and functional
synapses (Shi et al., 2020). Moreover, the presence of a stabilized
functional vascular network is also critical which requires the
improvement of the current models for better recapitulating the
physiopathology of these models.
3D co-culture models of blood vessels have been recently
developed which may be used as vascularization trunks for
tumor models. 3D models are much more relevant to study
these interactions because they better recapitulate cell behavior
and also better mirror in vivo gene expression and signaling.
3D co-culture models represent an attractive alternative to
animal models and may be used in drug screening to identify
better therapies.
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Anti-angiogenic therapy in GBM did not meet the initial
high expectations when tested in clinical trials. There was no
real clinical benefit in newly diagnosed and recurrent GBM
(maybe with exception of regorafenib). However, if clinical trials
allow to obtain a global vision of the therapeutic effect, they
do not consider patient subgroups. When considered, this may
allow a more precise vision of the therapeutic response. Another
drawback is variable study design and the criteria for determining
progression. Radiologic response criteria such as Macdonald
or RANO criteria may be misleading in monitoring clinical
responses to anti-angiogenic therapy. Thus, this is still not the
end of the road for anti-angiogenic therapy in GBM and more
promising data from clinical trials are expected to come.
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